CD22 and non-Hodgkin lymphoma: Inotuzumab ozogamicin (InO, CMC-544) is a CD22-targeted ADC combining a humanized IgG4 anti-CD22 mAb with calicheamicin, an enediyne antibiotic, which causes DNA damage and cell apoptosis.58,59 The combination of InO with rituximab in a phase 1/2 study (NCT00299494) of relapsed FL, DLBCL, and refractory aggressive NHL induced ORRs of 87%, 74%, and 20%, respectively.